Thermogenic
L-BAIBA (MitoBurn)
L-BAIBA is an exercise-linked metabolite with absorption data but no demonstrated fat-loss or performance benefit.
How it counts: Not part of the score
We show it on the label and count it as disclosed, but it never affects Dose, any sub-score or the grade. The basis below explains why.
- Clinical dose
- No established clinical dose
- Safety ceiling
- —
- Evidence
- weak
- Category
- Thermogenic
Evidence summary
Research confidence: low
No reference dose. L-BAIBA is a small molecule muscles release during exercise, sold as a fat-burning aid. In the only trial testing it for results, 500 mg a day for 8 weeks alongside diet and exercise did not change resting metabolism, body fat, blood pressure or heart rate compared with placebo (Allen 2026). Other human work only shows that 250-1,500 mg is absorbed into the blood; the 500 mg on this label matches the dose that showed no effect.
Research sources
- Effects of L-BAIBA supplementation with and without grains of paradise on changes in resting metabolic rate, body composition, and cardiometabolic risk factors (Allen et al., Nutrition Journal 2026)(opens in new window)
- Dose-Response Absorption Kinetics of Oral L-Beta-Aminoisobutyric Acid (L-BAIBA) Supplementation in Healthy Men and Women (Krieger et al., J Diet Suppl 2022)(opens in new window)
12 adults, randomized double-blind crossover: single 250, 500 and 1,500 mg doses raised plasma L-BAIBA dose-dependently over 5 h; no adverse events. Absorption only, no outcome measured. Funded by Nanjing Nutrabuilding Bio-tech (NNB).
- Allen et al. 2026, full text (PMC)(opens in new window)
37 overweight/obese adults, 56 days of diet plus exercise: 500 mg/day MitoBurn, or 500 mg MitoBurn + 40 mg CaloriBurn, vs placebo. No group differences in resting metabolic rate, fat mass, blood pressure or heart rate. Funded by NNB Nutrition, which supplied both products.